|
Keywords
|
Urothelium Botulinum toxin Liposome |
|
Target Audience
|
Urologists, urogynecologists, clinical and basic researchers |
|
Aims and Objectives
|
Urothelial dysfunction might play a role in the abnormality of expression of sensory receptors or release of transmitters in the suburothelial nerves or interstitial cells. In this regard, intravesical treatment to inhibit receptor expression or transmitter release might provide good therapeutic effects in the treatment of sensory urgency, interstitial cystitis/bladder pain syndrome, and overactive bladder (OAB). Intravesical pharmacotherapy has been used for the treatment of refractory OAB and IC/BPS, however, an important obstacle in the success of intravesical drug delivery arises from the low permeability of bladder epithelium. This workshop helps participants select suitable intravesical treatment for urothelial associated LUTD.
|